Marketing Strategy for a Phase 3 Drug: What to Do Before Approval
What marketing teams can and cannot do while a drug is in phase 3: research, disease education, list building, measurement setup, and launch readiness.
The short answer
While a drug is in phase 3, it cannot be promoted, so marketing work focuses on preparation: understanding the market and patient journey, unbranded disease education, building and validating HCP target lists, setting up data and measurement partners, testing concepts in research, and planning the launch media. Most launch success is decided by how well these foundations are built before approval.
A phase 3 drug cannot be promoted. That does not mean marketing waits. The months before approval are when teams build what launch will run on. Launches that struggle often trace their problems to this period: target lists built in a rush, measurement set up after launch, or no understanding of why patients go undiagnosed.
What is off limits
- Claiming or implying the investigational drug is safe or effective.
- Branded advertising before approval.
- Promotional activity that gets ahead of the label.
Scientific exchange, handled by medical affairs, follows different rules. Keep marketing and medical activities clearly separated.
What marketing can do
1. Understand the market
- Patient journey research: where patients get stuck, from symptoms to diagnosis to treatment.
- HCP research on current treatment choices and unmet needs.
- Payer research on how the product might be covered.
See disease-state insights for pre-launch.
2. Disease education
Unbranded campaigns can raise awareness of a condition, encourage diagnosis, or support testing. These must not name or point to the investigational product. They also build audiences and learning that branded launch media can use later.
3. Build the target lists
- Define HCP segments and tiers from claims.
- Audit lists for specialty, location, and identity issues. See HCP target list audit.
- Match lists with media and data partners early to learn real match rates.
4. Set up data and measurement
- Choose measurement partners and agree methods before launch, including control groups.
- Validate tags and data flows. See prelaunch QA.
- Set a baseline: current awareness, treatment patterns, and diagnosis rates.
5. Prepare messages and creative
Research can test concepts and claims that may be supported if data reads out as expected. Plan for several label scenarios. Final materials wait for the approved label and review.
6. Plan launch media
- Draft media plans by label scenario.
- Line up endemic, point-of-care, and programmatic partners.
- Plan sequencing for the first 90 days. The drug launch media plan article covers pre-launch to year one.
Scenario planning
Phase 3 results and label language are uncertain. Build plans for at least three cases: label as hoped, narrower label, delayed approval. For each, note what changes in target lists, messages, and spend.
A pre-launch timeline
| Time before expected approval | Focus |
|---|---|
| 24 to 18 months | Market research, patient journey, segmentation |
| 18 to 12 months | Disease education, list building, partner selection |
| 12 to 6 months | Measurement setup, creative development by scenario |
| 6 to 0 months | Media booking, QA, launch readiness review |
Smaller companies compress this. See launching a first precision medicine at a small biotech.
Common mistakes
- Waiting for approval to start list building and measurement setup.
- Disease education that hints at the product.
- One launch plan with no label scenarios.
- No baseline, so launch impact cannot be measured.
Practical takeaway
At the 12-month mark, check three things: target lists matched with media partners, measurement partner contracted with a control design, and launch plans written for more than one label scenario. If any is missing, that is the priority.
Frequently asked questions
Can you market a drug before FDA approval?
You cannot promote an investigational drug as safe or effective for an unapproved use. Companies can run unbranded disease education and certain corporate communications, within FDA rules and company policy.
When should launch planning start?
Many companies start serious commercial planning during phase 3, often two to three years before expected approval, with intensity rising in the final year.
What is disease awareness advertising?
Unbranded communication about a condition, its symptoms, or diagnosis that does not name or suggest a specific product.
Sources
- FDA, Prescription Drug Advertising
- FDA, Office of Prescription Drug Promotion (OPDP)
- eCFR, 21 CFR Part 202, Prescription Drug Advertising
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.